Keith Michael Gottesdiener is CEO & President at RHYTHM PHARMACEUTICALS, INC. (RYTM). They have made 9 open-market trades across 2 companies since 2018, most recently 2024-10-08.
CIK 0001615856
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $75K since 2018, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RYTM | SELL | 2019-03-15 | 2019-03-19 | $30.09 | $619K | -9.7% | -13.6% | -24.8% |
| RYTM | SELL | 2019-03-13 | 2019-03-15 | $30.06 | $513K | -0.7% | -14.9% | -21.6% |
| RYTM | SELL | 2019-02-26 | 2019-02-28 | $30.03 | $128K | +1.7% | -4.2% | -13.0% |
| RYTM | SELL | 2019-02-15 | 2019-02-20 | $30.02 | $748K | -3.1% | +1.9% | -5.4% |
| RYTM | SELL | 2019-02-13 | 2019-02-15 | $30.00 | $118K | -4.1% | +1.2% | -10.7% |
| RYTM | SELL | 2019-01-22 | 2019-01-24 | $30.05 | $945K | -2.6% | +2.1% | -12.2% |
| RYTM | SELL | 2019-01-18 | 2019-01-22 | $30.01 | $607K | -10.6% | -9.0% | -15.0% |
| RYTM | SELL · 10b5-1 | 2019-01-16 | 2019-01-17 | $30.00 | $20K | -11.7% | -1.9% | -15.3% |
| RYTM | SELL · 10b5-1 | 2018-12-03 | 2018-12-06 | $30.00 | $17K | +1.4% | +0.7% | -7.8% |
| RYTM | SELL | 2018-11-02 | 2018-11-06 | $30.08 | $496K | -3.7% | -6.5% | -6.6% |
| ICPT | BUY | 2018-04-09 | 2018-04-09 | $64.00 | $75K | -2.0% | +2.0% | +33.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.